PURPOSE: To determine the effect of vascular endothelial growth factor (VEGF) TrapR1R2 on bFGF-induced experimental corneal neovascularization (NV). METHODS: Control pellets or pellets containing 80 ng bFGF were surgically implanted into wild-type C57BL/6 and VEGF-LacZ mouse corneas. The corneas were photographed, harvested, and the percentage of corneal NV was calculated. The harvested corneas were evaluated for VEGF expression. VEGF-LacZ mice received tail vein injections of an endothelial-specific lectin after pellet implantation to determine the temporal and spatial relationship between VEGF expression and corneal NV. Intraperitoneal injections of VEGF TrapR1R2 or a human IgG Fc domain control protein were administered, and bFGF pellet-induced corneal NV was evaluated. RESULTS: NV of the corneal stroma began on day 4 and was sustained through day 21 following bFGF pellet implantation. Progression of vascular endothelial cells correlated with increased VEGF-LacZ expression. Western blot analysis showed increased VEGF expression in the corneal NV zone. Following bFGF pellet implantation, the area of corneal NV in untreated controls was 1.05+/-0.12 mm2 and 1.53+/-0.27 mm2 at days 4 and 7, respectively. This was significantly greater than that of mice treated with VEGF Trap (0.24+/-0.11 mm2 and 0.35+/-0.16 mm2 at days 4 and 7, respectively; p<0.05). CONCLUSIONS: Corneal keratocytes express VEGF after bFGF stimulation and bFGF-induced corneal NV is blocked by intraperitoneal VEGF TrapR1R2 administration. Systemic administration of VEGF TrapR1R2 may have potential therapeutic applications in the management of corneal NV.
PURPOSE: To determine the effect of vascular endothelial growth factor (VEGF) TrapR1R2 on bFGF-induced experimental corneal neovascularization (NV). METHODS: Control pellets or pellets containing 80 ng bFGF were surgically implanted into wild-type C57BL/6 and VEGF-LacZ mouse corneas. The corneas were photographed, harvested, and the percentage of corneal NV was calculated. The harvested corneas were evaluated for VEGF expression. VEGF-LacZ mice received tail vein injections of an endothelial-specific lectin after pellet implantation to determine the temporal and spatial relationship between VEGF expression and corneal NV. Intraperitoneal injections of VEGF TrapR1R2 or a human IgG Fc domain control protein were administered, and bFGF pellet-induced corneal NV was evaluated. RESULTS: NV of the corneal stroma began on day 4 and was sustained through day 21 following bFGF pellet implantation. Progression of vascular endothelial cells correlated with increased VEGF-LacZ expression. Western blot analysis showed increased VEGF expression in the corneal NV zone. Following bFGF pellet implantation, the area of corneal NV in untreated controls was 1.05+/-0.12 mm2 and 1.53+/-0.27 mm2 at days 4 and 7, respectively. This was significantly greater than that of mice treated with VEGF Trap (0.24+/-0.11 mm2 and 0.35+/-0.16 mm2 at days 4 and 7, respectively; p<0.05). CONCLUSIONS: Corneal keratocytes express VEGF after bFGF stimulation and bFGF-induced corneal NV is blocked by intraperitoneal VEGF TrapR1R2 administration. Systemic administration of VEGF TrapR1R2 may have potential therapeutic applications in the management of corneal NV.
Authors: Balamurali K Ambati; Miho Nozaki; Nirbhai Singh; Atsunobu Takeda; Pooja D Jani; Tushar Suthar; Romulo J C Albuquerque; Elizabeth Richter; Eiji Sakurai; Michael T Newcomb; Mark E Kleinman; Ruth B Caldwell; Qing Lin; Yuichiro Ogura; Angela Orecchia; Don A Samuelson; Dalen W Agnew; Judy St Leger; W Richard Green; Parameshwar J Mahasreshti; David T Curiel; Donna Kwan; Helene Marsh; Sakae Ikeda; Lucy J Leiper; J Martin Collinson; Sasha Bogdanovich; Tejvir S Khurana; Masabumi Shibuya; Megan E Baldwin; Napoleone Ferrara; Hans-Peter Gerber; Sandro De Falco; Jassir Witta; Judit Z Baffi; Brian J Raisler; Jayakrishna Ambati Journal: Nature Date: 2006-10-18 Impact factor: 49.962
Authors: Z Poltorak; T Cohen; R Sivan; Y Kandelis; G Spira; I Vlodavsky; E Keshet; G Neufeld Journal: J Biol Chem Date: 1997-03-14 Impact factor: 5.157
Authors: Surekha Maddula; Don K Davis; Soumya Maddula; Michael K Burrow; Balamurali K Ambati Journal: Ophthalmology Date: 2011-03 Impact factor: 12.079
Authors: Danial Roshandel; Medi Eslani; Alireza Baradaran-Rafii; Albert Y Cheung; Khaliq Kurji; Sayena Jabbehdari; Alejandra Maiz; Setareh Jalali; Ali R Djalilian; Edward J Holland Journal: Ocul Surf Date: 2018-06-20 Impact factor: 5.033
Authors: Rajiv R Mohan; Sunilima Sinha; Ashish Tandon; Rangan Gupta; Jonathan C K Tovey; Ajay Sharma Journal: PLoS One Date: 2011-04-12 Impact factor: 3.240
Authors: Shiven Kapur; Adam P Silverman; Anne Z Ye; Niv Papo; Darren Jindal; Mark S Blumenkranz; Jennifer R Cochran Journal: Bioeng Transl Med Date: 2017-02-17